-
Innovation Ranking
Innovation Ranking – OC Oerlikon Corporation AG
OC Oerlikon Corporation AG (Oerlikon) is a provider of advanced materials, surface solutions and materials processing. It develops production systems, components, and services for high-technology products; and provides turnkey solutions for the manufacturing of protective coatings for precision tools and components, and equipment for textile production and propulsion technology. Oerlikon serves customers in aerospace, automotive, general industries and tooling, energy, apparel and industrial textiles, and agriculture sectors in Europe, Asia-Pacific, North America and other regions. The company has sales, service...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KVA-12123 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KVA-12123 in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KVA-12123 in Colorectal Cancer Drug Details: KVA-12123 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Licaminlimab in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Licaminlimab in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Licaminlimab in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: Licaminlimab (OCS-02)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KVA-12123 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KVA-12123 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KVA-12123 in Non-Small Cell Lung Cancer Drug Details: KVA-12123 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target BCMA And CD38 For Relapsed And RefractoryMultiple Myeloma in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target BCMA And CD38 For Relapsed And RefractoryMultiple Myeloma in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KVA-12123 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KVA-12123 in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KVA-12123 in Melanoma Drug Details: KVA-12123 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Everolimus in Metastatic Transitional (Urothelial) Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Everolimus in Metastatic Transitional (Urothelial) Tract Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in Metastatic Transitional (Urothelial) Tract Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KVA-12123 in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KVA-12123 in Colon Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KVA-12123 in Colon Cancer Drug Details: KVA-12123 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KVA-12123 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KVA-12123 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KVA-12123 in Pancreatic Cancer Drug Details: KVA-12123 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KVA-12123 in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KVA-12123 in Bladder Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KVA-12123 in Bladder Cancer Drug Details: KVA-12123 is under development for...